Is Amgen Inc. (AMGN) a Buy, Sell, or Hold?
Amgen Inc.
NASDAQ:AMGN
$355.25 USD
-$5.2 (-1.44%)
- Volume
- 1.86M
- Average Volume
- 2.72M
- Market Capitalization
- $191.73B
- P/E Ratio
- 24.53
- Dividend Yield
- 2.76%
- Price Target
- $357.50
- Year High
- $391.29
- Year Low
- $269.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.67
- Current Ratio
- $1.26
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert A. Bradway |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | AMGN |
| CUSIP | 031162100 |
| CIK | 0000318154 |
| Web | https://www.amgen.com |
| Phone | 805 447 1000 |
| Currency | USD |
| Employees | 31500 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 6.24 |
| Payout Ratio | 0.67 |
| Current Ratio | 1.26 |
| Quick Ratio | 1.01 |
| Cash Ratio | 0.48 |
Sales & Book Value
| Annual Sales | $36.74B |
| Price / Sales | 5.15 |
| Cash Flow | 15.92 |
| Price / Cash Flow | 22.30 |
| Price / Book | 20.87 |
Price Target and Rating
| Average Stock Price Forecast | $357.50 |
| High Stock Price Forecast | $427.00 |
| Low Stock Price Forecast | $185.00 |
| Forecast Upside/Downside | -0.63% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 38 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $14.23 |
| Trailing P/E Ratio | 24.53 |
| PEG Ratio | 0.79 |
| P/E Growth | 0.79 |
| Net Income | $7.71B |
| Net Margin | 20.95% |
| Pretax Margin | 24.40% |
| Return on Equity | 89.41% |
| Return on Assets | 8.43% |
Financials Score
| AltmanZ Score | 1.94 |
| Piotroski Score | 8.00 |
| Working Capital | 6.52B |
| Total Assets | 92.5B |
| Ebit | 11.79B |
| Market Cap | 194.54B |
| Total Liabilities | 83.31B |
Poll Results
About Amgen Inc. (NASDAQ:AMGN) Stock
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteopo ... rosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
2026-07-14 18:51:16
Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.
HRMY vs. AMGN: Which Stock Is the Better Value Option?
2026-07-14 12:40:26
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
2026-07-14 11:51:03
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
2026-07-13 10:01:23
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMGN DCF Analysis: Intrinsic Value $292 vs Price $363
2026-07-13 07:30:00
On July 13, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown significant price performance over the past year with a 24.6
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
2026-07-09 11:35:25
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
2026-07-07 14:45:00
Near-term headwinds could sink the stock, but there is more to the story.
2026-07-07 12:30:17
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Frequently Asked Questions
-
What is the current Amgen Inc. (AMGN) stock price?
-
Amgen Inc.(NASDAQ:AMGN) stock price is $355.25 in the last trading session. During the trading session, AMGN stock reached the peak price of $391.29 while $269.77 was the lowest point it dropped to. The percentage change in AMGN stock occurred in the recent session was --1.44% while the dollar amount for the price change in AMGN stock was -$-5.2.
-
AMGN's industry and sector of operation?
-
The NASDAQ listed AMGN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of AMGN?
-
James E. Bradner | EVP of Research & Development, Artificial Intelligence and Data
Andrew H. Martin | Senior VP & GM of U.S. Business Operations
Jasper van Grunsven | Senior Vice President of Rare Disease, Global Commercial Capabilities & Innovation
Murdo Gordon | Executive Vice President of Global Markets and Policy
Peter H. Griffith | Executive Vice President & Chief Financial Officer -
How many employees does AMGN have?
-
Number of AMGN employees currently stands at 31500. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US.
-
Link for AMGN official website?
-
Official Website of AMGN is: https://www.amgen.com
-
How do I contact AMGN?
-
AMGN could be contacted at phone #805 447 1000 and can also be accessed through its website. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US.
-
How many shares of AMGN are traded daily?
-
The average number of AMGN shares traded daily for last 3 months was 2.72M.
-
What is the market cap of AMGN currently?
-
The market value of AMGN currently stands at $191.73B with its latest stock price at $355.25